The role of oxidative stress in the occurrence and development of diabetes mellitus is both critical and pivotal. Several molecular event cascade in different metabolic pathways such as glycolytic, hexosamine, protein kinase C, polyol and advanced glycation end-product (AGE) pathways have been identified as pro-oxidative processes and are usually up-regulated in the diabetics. Inhibition of glyceraldehyde-3-P dehydrogenase by poly-ADP-ribose polymerase 1 and subsequent accumulation of the enzyme substrate (glyceraldehyde-3-P) appears to be central to diabetes-associated oxidative stress. Increased level of glyceraldehyde-3-P activates two major pro-oxidative pathways in diabetes: (i) It activates the AGE pathway, precisely the synthesis of methylglyoxal from non-enzymatic dephosphorylation of the triose phosphates (ii) It activates protein kinase C (PKC) pathway by promoting the synthesis of diacylglycerol. In addition, it causes the accumulation of glycolytic metabolites upstream, and this leads to excessive stimulation of other pro-oxidative pathways such as hexosamine and polyol pathways. This review tends to highlight the main oxidative processes associated with diabetes mellitus.
Glycemic homeostasis refers to glucose balance or control within circulation in living organisms. It is normally and largely compromised in diabetes. The compromise when exacerbated, leads to several complications including retinopathy, nephropathy and neuropathy which are collectively known as diabetic complications and are the principal actors in co-morbidity and eventual mortality often associated with diabetes. The ability of therapeutic compounds including medicinal plants to restore glycemic balance or homeostasis in hyperglycemic condition is an index of their antidiabetic function and relevance. Alloxan and streptozotocin are the most popular diabetogenic agents used for assessing the antidiabetic or hypoglycemic capacity of test compounds. Notably, alloxan is far less expensive and more readily available than streptozotocin. On this ground, one will logically expect a preference for use of alloxan in experimental diabetes studies. Surprisingly, a sub meta-analysis of randomly selected studies conducted within the last one and half decade revealed otherwise. This observation necessitated the review of alloxan as a diabetogenic agent in animal studies.
8 December 2017 in BMC Complementary and Alternative Medicine
Ethnobatanical survey associates Sapium ellipticum (SE) with antidiabetic usage among other medicinal functions in different parts of Africa. More importantly, previous studies on the plant extract in our laboratory showed that SE has significant effects on the activities of carbohydrate metabolizing enzymes such as glucokinase, glucose-6-phosphatase, α-amylase and α-glucosidase. In view of these, the anti-diabetic potential of the plant leaf extract in streptozotocin (STZ)-induced diabetes rat model (Wistar strain) was examined. Diabetes was induced in experimental animals via single intraperitoneal dose (55 mg/kg BW) of freshly prepared STZ. SE was evaluated at 400 and 800 mg kg−1 of body weight (BW), against metformin (12 mgkg−1 BW). Treatments were done orally (p.o), twice daily at 8 h interval for a period of 21 days. SE significantly reduced fasting blood glucose (FBG) level by 46.5 and 44.4% (400 and 800 mg dosage respectively) compared to initial diabetic values. However, the effects were significantly lower than 72.6% glucose reduction produced by metformin. Hepatic and skeletal muscle glycogens were observed to increase by 27.06 and 12.55% respectively in SE-treated rats (800 mg dosage) compared to their corresponding values in diabetic control animals. Plasma and pancreatic insulin contents were also improved (31.77 and 52.34% respectively) by SE administration. The histopathological examination of the pancreas indicates beta cells regeneration in the treated animals, particularly in diabetic rats treated with 800 mg dosage of the extract compared to the diabetic control animals and metformin group. The presence of phenolic compounds namely amentoflavone, lupeol and luteolin-7-O-glucoside in SE as characterized and reported in our previous study is likely responsibly for the antidiabetic effects of the plant extract noted in the present study. The outcome of this study provides scientific basis in support of the medicinal relevance of SE and lend credence to its utilization in folk medicine for the treatment of diabetes and other oxidative stress-related ailments.
7 June 2017 in International Scholarly Research Notices
Dyslipidemia is a common metabolic disorder especially in diabetes mellitus (DM). In this study, the ability ofSapium ellipticum(SE) leaf extract to restore lipid homeostasis in streptozotocin-induced diabetes was examined. DM was induced in experimental rats (Wistar strains) using single intraperitoneal dose (55 mg/kg body weight) of streptozotocin (STZ). Treatment of diabetic rats with SE was oral (p.o), at doses of 400 and 800 mg kg−1BW, twice daily at 8 h interval for 21 days. Lipid parameters were analyzed in the serum of rats using test kits. SE caused a significant () reduction in STZ-induced hypercholesterolemia in a dose dependent pattern (13.7 and 17.89%). These effects were comparable to that provided by metformin (15.45%), a standard antidiabetic drug. Similar pattern was noted with serum triglycerides (TG) (10.63 and 19.06%) and LDL (31.47 and 25.97%). Adipose tissue TG level was improved to near normal. Besides, the cardiovascular risk predictors in terms of atherogenic index of plasma (AIP) and LDL/HDL ratio were lowered by 57.85 and 44.12%, respectively. However, the extract failed to significantly reverse the STZ-induced decline in serum HDL. Overall, with AIP value of 0.28 and LDL/HDL ratio of 0.91, SE demonstrated the potential to maintain lipid homeostasis in the diabetics.
• Polyherbal formulation composed of Hibiscus sabdariffa and aloe barbadensis is commonly patronized in Southwestern Nigeria. • Scales through acute and sub chronic toxicity testing at the recommended dose (10 mL/kg BW). • The polyherbal contains compounds with known biological effects associable with its folklore applications • Study outcome suggests herbal safety for the polyherbal formulation within the recommended dose. • Long period of therapeutic application requires great caution in terms of how much is consumed.
Parquetina nigrescens is a folklore plant in Africa, particularly Nigeria, where its consumption is believed to stimulate red blood cells production. On this basis, the erythropoietic potential of the plant was evaluated in Cephalosporin-induced anaemia model, using Wistar rats as experimental subjects. Thirty-two male rats were randomly assigned to four groups (n = 8). Group 1 animals served as control, and experimental anaemia was induced in other groups of animals via oral administration of cephalosporin (10 mg/kg BW) for a period of seven days. Animals in groups III and IV were treated orally with aqueous extract of P. nigrescens at respective dosage of 250 and 500 mg/kg BW, twice daily for a period of 10 days; while group II animals were left untreated. All animals were thereafter fasted overnight and sacrificed by cervical decapitation. Blood was collected via the retro-orbital sinus and used for biochemical analyses. The results obtained showed that cephalosporin effectively induced anaemia as evidenced by significant changes in erythropoietic indices of the untreated anaemic animals. Treatment of anaemic animals with P. nigrescens particularly at a dosage of 250 mg/kg BW significantly (P˂0.05) boosted the levels of RBC (35.8%), Hb (25.2%), PCV (39.4%), cobalt (70.9%), vitamin C (82.6%), and concomitantly decreased erythropoietin level (18%) relative to untreated anaemic animals. The observations made in this study support the local use of Parquetina nigrescens as blood tonic and therapy for anaemia. The botanical may therefore be a useful supplement for patients placed on antibiotics which are often associated with haemolysis.